Sensius
Rotterdam
About Sensius
Sensius fundamentally changes the risk-reward balance when treating cancer. Addition of Sensius’ thermotherapy to cancer treatment improves both outcome and quality of life, where mainstay treatments (radio- and chemotherapy) are inherently toxic. Sensius is a medical device company that has built a bespoke cancer therapy device using proprietary thermal technology and software. The device is designed by clinicians who use their skills and experience to craft unique thermal collars to treat initially head and neck cancer. Seventy patients have been treated with the device. A study demonstrated 81.8% of the patients having a complete response at 12 weeks following radiotherapy. The Company is now moving to build a CE marked device: already 20 interested parties are intending to purchase the device as soon as it is CE/FDA-marked. A roadmap for other cancer treatments is available.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $14.1M
- Last round: Grant (Feb 2023)
- Website: sensiusthermotherapy.com
- Phone: +31 10 704 4853
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device, Oncology
Social Profiles
Canonical: https://fsome.com/organization/sensius-69991 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.